Cancer-associated myositis: A 35-year retrospective study of a monocentric cohort

Rheumatology International

Volumn 34, Issue 4, 2014, Pages 565-569

  Neri, Rossella ^a   Simone, Barsotti ^a   Iacopetti, Valentina ^a   Iacopetti, Giacomo ^a   Pepe, Pasquale ^a   D'Ascanio, Anna ^a   Tavoni, Antonio Gaetano ^b   Mosca, Marta ^a   Bombardieri, Stefano ^a  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Cancer; Myositis; Outcomes

Indexed keywords

CREATINE KINASE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; JO 1 ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; AUTOANTIBODY; BIOLOGICAL MARKER;

ADULT; ARTHRITIS; ARTICLE; CANCER ASSOCIATED MYOSITIS; CANCER SCREENING; CLINICAL ASSESSMENT; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COUNTER IMMUNOELECTROPHORESIS; DERMATOMYOSITIS; DISEASE ASSOCIATION; DRUG MEGADOSE; DYSPHAGIA; DYSPHONIA; DYSPNEA; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MUSCLE BIOPSY; MYOSITIS; PRIORITY JOURNAL; PROGNOSIS; RARE DISEASE; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; SURVIVAL RATE; AGE; BLOOD; DEGLUTITION DISORDERS; EPIDEMIOLOGY; ITALY; KAPLAN MEIER METHOD; MORTALITY; NEOPLASMS; PREDICTIVE VALUE; PREVALENCE; RISK FACTOR; TIME;

AGE FACTORS; AUTOANTIBODIES; BIOLOGICAL MARKERS; CREATINE KINASE; DEGLUTITION DISORDERS; DERMATOMYOSITIS; FEMALE; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOSITIS; NEOPLASMS; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS;

EID: 84897056171     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-013-2910-1     Document Type: Article

References (21)

1. Bohan A, Peter JB (1975) Polymyositis and dermatomyositis (first of two parts). N Engl J Med 292(7):344-347
2. Mammen AL (2010) Dermatomyositis and polymyositis. Ann N Y Acad Sci 1184:134-153
3. Mosca M, Neri R, Pasero G, Bombardieri S (2000) Treatment of the idiopathic inflammatory myopathies: a retrospective analysis of 63 Caucasian patients longitudinally followed at a single center. Clin Exp Rheumatol 18:451-456 (Pubitemid 30616940)
4. Neri R, Mosca M, Grazzini T, Tavoni A, Pasero G, Bombardieri S (2001) Long term functional outcome of idiopathic inflammatory myopathies. Reumatismo 53:40-45
5. Wakata N, Kurihara T, Saito E, Kinoshita M (2002) Polymyositis and dermatomyositis associated with malignancy: a 30-year retrospective study. Int J Dermatol 41(11):729-734 (Pubitemid 35422835)
6. Lakhanpal S, Bunch TW, Ilstrup DM, Melton LJ 3rd (1986) Polymyositis-dermatomyositis and malignant lesions: does an association exist? Mayo Clin Proc 61:645-653 (Pubitemid 16029464)
7. Sigurgeirsson B, Lindelöf B, Edhag O, Allander E (1992) Risk of cancer in patients with dermatomyositis or polymyositis. A population-based study. N Engl J Med 326(6):363-367
8. Airio A, Pukkala E, Isomäki H (1995) Elevated cancer incidence in patients with dermatomyositis: a population based study. J Rheumatol 22:1300-1303
9. Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr (1995) Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control 6:9-13
10. Maoz CR, Langevitz P, Livneh A, Blumstein Z, Sadeh M, Bank I et al (1998) High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis. Semin Arthritis Rheum 27:319-324 (Pubitemid 28176237)
11. Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A et al (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet 357:96-100 (Pubitemid 32094911)
12. Chen YJ, Wu CY, Shen JL (2001) Predicting factors of malignancy in dermatomyositis and polymyositis: a case-control study. Br J Dermatol 144:825-831
13. Limaye V, Luke C, Tucker G, Hill C, Lester S, Blumbergs P et al (2013) The incidence and associations of malignancy in a large cohort of patients with biopsy-determined idiopathic inflammatory myositis. Rheumatol Int 33(4):965-971
14. András C, Ponyi A, Constantin T, Csiki Z, Szekanecz E, Szodoray P et al (2008) Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study. J Rheumatol 35:438-444 (Pubitemid 351374417)
15. Chinoy H, Fertig N, Oddis CV, Ollier WER, Cooper RG (2007) The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 66:1345-1349 (Pubitemid 47492479)
16. Legault D, McDermott J, Crous-Tsanaclis AM, Boire G (2008) Cancer-associated myositis in the presence of anti-Jo1 autoantibodies and the antisynthetase syndrome. J Rheumatol 35:169-171
17. Watkins J, Farzaneh-Far R, Tahir H, Wykes F, Studdy PR, Beynon HLC (2004) Jo-1 syndrome with associated poorly differentiated adenocarcinoma. Rheumatology 43:389-390 (Pubitemid 38313196)
18. Ghirardello A, Bassi N, Palma L, Borella E, Domeneghetti M, Punzi L, Doria A (2013) Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep 15:335
19. Lee S-W, Jung SY, Park M-C, Park Y-B, Lee S-K (2006) Malignancies in Korean patients with inflammatory myopathy. Yonsei Med J 47:519-523 (Pubitemid 44322979)
20. Ponyi A, Constantin T, Garami M, András C, Tállai B, Váncsa A et al (2005) Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci 1051:64-71 (Pubitemid 41362733)
21. Fujimoto M (2013) Myositis-specific autoantibodies. Brain Nerve 65(4):449-460